Intelligence Feed event · Equity · 2026-09-01

    Novartis Reports Positive Phase III Results for Remibrutinib in Multiple Sclerosis

    Question

    Novartis Reports Positive Phase III Results for Remibrutinib in Multiple Sclerosis

    Direct answer

    Novartis confirmed that remibrutinib met primary and secondary endpoints in both REMODEL-1 and REMODEL-2 Phase III trials for relapsing multiple sclerosis. The oral BTK inhibitor outperformed standard-of-care teriflunomide on annualized relapse reduction and lesion suppression while sustaining a favorable safety profile.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-01
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Novartis Reports Positive Phase III Results for Remibrutinib in Multiple Sclerosis”, revision 1, evidence through 2026-09-01. https://marketontology.com/market-events/2026-09-01/novartis-reports-positive-phase-iii-results-for-remibrutinib-in-multiple-scleros-719cf5

    EQUITY
    Novartis Reports Positive Phase III Results for Remibrutinib in Multiple Sclerosis
    Novartis confirmed that remibrutinib met primary and secondary endpoints in both REMODEL-1 and REMODEL-2 Phase III trials for relapsing multiple sclerosis. The oral BTK inhibitor outperformed standard-of-care teriflunomide on annualized relapse reduction and lesion suppression while sustaining a favorable safety profile.
    NVS
    Impact
    71
    SEP 1
    SIG
    85%
    NVS
    Novartis Reports Positive Phase III Results for Remibrutinib in Multiple Sclerosis
    Novartis confirmed that remibrutinib met primary and secondary endpoints in both REMODEL-1 and REMODEL-2 Phase III trials for relapsing multiple sclerosis. The oral BTK inhibitor outperformed standard-of-care teriflunomide on annualized relapse reduction and lesion suppression while sustaining a favorable safety profile.
    → Statistically superior Phase III efficacy versus teriflunomide derisks Novartis neurology pipeline revenue ahead of regulatory submissions.
    Impact
    Novartis confirmed that remibrutinib met primary and secondary endpoints in both REMODEL-1 and REMODEL-2 Phase III trials for relapsing multiple sclerosis. The oral BTK inhibitor outperformed standard-of-care teriflunomide on annualized relapse reduction and lesion suppression while sustaining a favorable safety profile.
    Affected
    NVS
    Transmission
    Statistically superior Phase III efficacy versus teriflunomide derisks Novartis neurology pipeline revenue ahead of regulatory submissions.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    NVSneurology pipeline commercialization deriskingUp1-3mPositive Phase III REMODEL-1 and REMODEL-2 trial readouts for remibrutinib.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month